Fresenius Kabis Pharmaceutical Tender

ScopeGerman pharmaceutical company Fresenius Kabi announced a proposal to expand its pharmaceutical manufacturing capabilities at the Melrose Park village site in Illinois US. The expanded facility will be used to produce generic sterile injectable pharmaceuticals for hospitals and clinics across the US. Construction commenced in September 2017 and the facility is expected to be fully operational by 2026. The expansion will create new jobs for construction and highly skilled workers in Melrose Park. The expansion will see the construction of new buildings at Fresenius Kabis existing 124267ft plant In Melrose Park which was built in 2008 at 2020 N Ruby St. The site is located in a general industrial area in the outskirts of Chicago five miles away from the OHare International Airport. It employs approximately 700 people. The plant currently produces a wide range of generic injectable medicines for the treatment of critically and chronically ill patients. Fresenius Kabi will add four new buildings to the site with a total floor space of 130000ft. The facility will include space for highly automated manufacturing offices warehousing of materials and utilities. The expansion is expected to support the production of injectable drugs used for anaesthesia pain management cancer treatment and eliminating infections. The project will be completed to meet the latest regulatory and quality requirements. The new facility will be equipped with a state-of-the-art urban manufacturing campus including fully-automated aseptic filling lines and sophisticated isolator technology as well as expanded freeze capabilities and formulation areas. It will also include a dedicated warehouse for raw materials and components alongside an administration building with a conference centre laboratories office spaces and a cafeteria.